Pivotal clinical trial enrollment of Blacks in multiple sclerosis or neuromyelitis spectrum disorder: When will we achieve parity?

Authors

Jagannadha AvasaralaFollow
Phenu Zachariah, Advocate Aurora HealthFollow
Breck Turner

Recommended Citation

Avasarala J, Zachariah P, Turner B. Pivotal clinical trial enrollment of Blacks in multiple sclerosis or neuromyelitis spectrum disorder: when will we achieve parity?. CNS Spectr. 2022;27(5):527-529. doi:10.1017/S1092852921000183

Affiliations

Aurora Health Center, Racine

Abstract

Patient enrollment in people of color among pivotal trials for multiple sclerosis (MS) and neuromyelitis spectrum disorder (NMOSD) continues to be dismal. It is disappointing that no clinical trial sponsored by a pharmaceutical industry or otherwise, investigating any of the disease-modifying drugs, has tackled this glaring inequity head on. The disease characteristics and phenotype of MS or NMOSD among Blacks and Hispanics are typically aggressive and for this reason alone, if not for any other metric, there needs to a radical shift in allotment of funds devoted to promoting drug research in minority populations.

Document Type

Article

PubMed ID

33563348